There is experimental evidence that some antioxidant flavonoids show therapeutic potential in the treatment of hepatitis C through inhibition of hepatitis C virus (HCV) replication. We examined the effect of treatment with the flavonols quercetin and kaempferol, the flavanone taxifolin and the flavone apigenin on HCV replication efficiency in an in vitro model. While all flavonoids studied were able to reduce viral replication at very low concentrations (ranging from 0.1 to 5 mM), quercetin appeared to be the most effective inhibitor of HCV replication, showing a marked anti-HCV activity in replicon-containing cells when combined with interferon (IFN)a. The contribution of oxidative/nitrosative stress and lipogenesis modulation to inhibition of HCV replication by quercetin was also examined. As expected, quercetin decreased HCV-induced reactive oxygen and nitrogen species (ROS/RNS) generation and lipoperoxidation in replicating cells. Quercetin also inhibited liver X receptor (LXR)a-induced lipid accumulation in LXRa-overexpressing and replicon-containing Huh7 cells. The mechanism underlying the LXRa-dependent lipogenesis modulatory effect of quercetin in HCV-replicating cells seems to involve phosphatidylinositol 3-kinase (PI3K)/AKT pathway inactivation. Thus, inhibition of the PI3K pathway by LY294002 attenuated LXRa upregulation and HCV replication mediated by lipid accumulation, showing an additive effect when combined with quercetin. Inactivation of the PI3K pathway by quercetin may contribute to the repression of LXRa-dependent lipogenesis and to the inhibition of viral replication induced by the flavonol. Combined, our data suggest that oxidative/nitrosative stress blockage and subsequent modulation of PI3K-LXRa-mediated lipogenesis might contribute to the inhibitory effect of quercetin on HCV replication.
Hepatitis C virus (HCV) is a positive-sensed, single-stranded RNA virus of the Flaviviridae family. 1 The genome of the human HCV encodes a polyprotein post-translationally cleaved by both viral and cellular proteases to produce four structural (core, E1, E2 and p7) and six non-structural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins. 2 HCV is a major cause of viral hepatitis, with estimated 150-200 million people infected worldwide. Approximately 70% of patients suffer from persistent infection, which causes chronic hepatitis and induces several complex mechanisms leading to inflammation, insulin resistance, steatosis, fibrosis and hepatocellular carcinoma. 3 Although the molecular mechanisms of HCV pathogenesis remain unclear, oxidative/nitrosative stress associated with reactive oxygen and nitrogen species (ROS/RNS) generation is emerging as a key step and a major initiator in the development and the progression of liver damage. [4] [5] [6] [7] Hepatic steatosis is often observed in patients with chronic hepatitis C and has been reported to be associated with insulin resistance and progression of fibrosis in the liver. 8,9 1 The molecular mechanisms of HCV-associated steatosis are poorly understood, 10 but they are mediated in large part by changes in lipogenic and oxidative stress-mediated proinflammatory cytokines gene expression associated with HCV proteins. 3, 7, 11 Thus, NS5A and core proteins colocalize on lipid droplets and activate various pathways of lipid metabolism, contributing to the development of HCV-associated steatosis. 12, 13 Moreover, lipid accumulation is necessary for successful HCV replication. 14 In this respect, we recently showed that HCV replication induces liver X receptor (LXR)a-mediated intracellular lipid accumulation, which in turn contributes to the efficient replication of HCV. 15 As oxidative stress has a central role in hepatitis C pathogenesis and progression, antioxidants have been proposed as therapeutic agents and drug coadjuvants. Much attention has been given to the potential health-promoting properties of flavonoids due to their reported wide range of activities in the prevention of common diseases, including coronary heart disease, cancer, neurodegenerative disease, gastrointestinal disorders and others. [16] [17] [18] Information on the potential benefits of flavonoids in the treatment of hepatitis C is relatively limited and sometimes contradictory, 19, 20 although some flavonoids, including quercetin, one of the most abundant flavonol-type flavonoids present in the human diet, seem to inhibit the replication of HCV. [21] [22] [23] On the basis of these data, in the current research we explored the effects of different natural antioxidant flavonoids on HCV replication in an in vitro model. We have previously described that important differences exist between flavonoids with different structural features in their capacity to abrogate the generation of different ROS/RNS. 24 Therefore, we examined the effect of the flavonols quercetin and kaempferol, the flavanone taxifolin and the flavone apigenin on HCV replication efficiency. Because results obtained indicated that quercetin was the most effective inhibitor of HCV replication, we aimed to investigate the molecular mechanisms involved in the modulation of HCV replication by this flavonol, focusing on its effects on ROS and RNS generation and lipid peroxidation, lipid accumulation and LXRa gene expression. In view of our previous findings showing that phosphatidylinositol 3-kinase (PI3K) pathway inhibition attenuates LXRa upregulation induced by HCV expression, 15 we also examined the role of the PI3K/AKT pathway in lipogenesis modulation by quercetin in our in vitro model.
MATERIALS AND METHODS Cells, Cell Culture and Treatment Protocols
Huh7 cells expressing full-length genotype 1b HCV replicons (HCV-G1) were established as previously described. 25 HCV-G1 cells were treated with human interferon (IFN)a-2b (PBL Interferon Source, Piscataway, NJ, USA) to eliminate replicons, and were used as control cured cells (Huh7). Huh7 and their derivatives were grown at 37 1C with a 5% CO 2 atmosphere in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum, 2 mM L-glutamine and 50 mg/ml gentamycin. HCV-G1 cells were selected by growth in culture medium containing G418. To prevent phenotypic drift, the cultures were used for only 8-10 weeks before reverting to frozen stocks from an early passage.
HCV-G1 cells were treated with the flavonols quercetin and kaempferol, the flavanone taxifolin and the flavone apigenin (Sigma-Aldrich, Madrid, Spain) ( Figure 1a ) in concentrations ranging from 0.1 to 5 mM for 48 h to evaluate their potential to inhibit HCV replication. Then, to analyze the molecular mechanisms involved in HCV inhibition by quercetin, we treated HCV-G1 cells with 0.1-0.5-1-5 mM quercetin with or without 0.5 U/ml IFNa-2b for 48 h. HCVreplicating cells were also treated with 50 U/ml IFNa-2b as a control of replication inhibition. Finally, we investigated the effect of PI3K chemical inhibition by treating repliconcontaining cells with LY294002 (Tocris Bioscience, Bristol, UK). 26 Thus, HCV-G1 cells were pretreated for 8 h with 50 mM LY294002 and then with or without quercetin (0.1-5 mM) or IFNa-2b (0.5 and 50 U/ml) for an additional 48 h. The vehicle used for all treatments was DMSO (0.05%). HCV-G1 control cells were incubated with DMSO alone (vehicle-treated cells).
Cell Viability in Cell Culture
The cell viability was assessed by the mitochondrial function, measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity for measuring cell proliferation and cytotoxicity as previously reported. 27 Briefly, cells were seeded in a 24-well plate and incubated with the different treatments. After treatment, the cells were incubated with 0.5 mg/ml MTT (Sigma-Aldrich) for 2 h at 37 1C. Subsequently, the media were aspirated and the cells were lysed with DMSO, where after the absorbance was read at 560 nm, with background subtraction at 650 nm, using a microplate reader (Bio-Rad Laboratories, Veenendaal, The Netherlands).
Flow Cytometry and Fluorescence Microscopy ROS and RNS production, lipid peroxidation and lipid accumulation were assessed by flow cytometry. The ROS and RNS production was analyzed by flow cytometry as the fluorescence of 2 0 ,7 0 -dichlorofluorescein (DCF) and ethidium (ETH), which are the oxidation products of 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (DCFH-DA; SigmaAldrich) and dihydroethidium (DHE; Molecular Probes, Leiden, The Netherlands) with a sensitivity for H 2 O 2 /NO-based radicals and O 2 À , respectively. 24 The lipid content and lipid peroxidation in cultured cells were determined using Bodipy 493/503 and Bodipy 581/591 C 11 , respectively (Invitrogen, Carlsbad, CA, USA). Briefly, cell monolayers were washed twice with PBS and incubated with the corresponding dye solution (5 mM for DCFH-DA and DHE or 1 mg/ml for Bodipy 493/503 and 581/591 C 11 ) for 15-45 min at 37 1C, then washed twice, resuspended in PBS, and analyzed on a FACSCalibur flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA). Fluorescence of 10,000 cells was analyzed using the Cell Quest software (Becton Dickinson Biosciences). Indeed, intracellular lipid accumulation was corroborated by fluorescence microscopy using a Nikon Eclipse Ti inverted microscope (Nikon, Amstelveen, The Netherlands). 15 Triglyceride and Free Fatty Acid Assay Intracellular triglyceride (TG) and free fatty acids (FFAs) accumulation were evaluated after the lysis of cells. We collected the supernatants of each group to determine the TG and FFA content in the cell lysates. TG and FFA levels were determined with kits from Biovision Research Products Quantitative Real-Time PCR Total RNA was obtained by using a Trizol reagent (Life Technologies, Carlsbad, CA, USA). First-strand cDNA was synthesized using the High-Capacity cDNA Archive Kit (Applied Biosystems, Weiterstadt, Germany). For gene expression assays, cDNA was amplified using multiplex realtime PCRs on a StepOne Plus (Applied Biosystems). 28 TaqMan primers and probes were derived from the commercially available TaqMans s Gene Expression Assays (Applied Biosystems) ( Table 1 ). Relative changes in gene expression levels were determined using the 2 À DDCt method. The cycle number at which the transcripts were detectable (CT) was normalized to the cycle number of GAPDH detection, referred to as DCT. PCR efficiency was determined by TaqMan analysis on a standard curve for targets and endogenous control amplifications that were highly similar. Replication studies were carried out using a SYBR Green kit (Roche Diagnostics GmbH) and two specific primer sets (5 0 -CCTGTGAGGAA CTACTGTCT-3 0 and 5 0 -CTATCAGGCAGTACCACAAG-3 0 for HCV, spanning 255 nucleotides of the 5 0 non-translated region; 5 0 -AAAGCCGCTCGCAAGAGTGCG-3 0 and 5 0 -ACTT GCCTCCTGCAAAGCAC-3 0 for histone H3). 6 The number of HCV RNA copies was determined by crossing point interpolation into standard curves, which were generated by reverse transcription of serially diluted, in vitro synthesized viral RNA (genomic) followed by quantitative PCR. The total amount of RNA per reaction was kept constant (1 mg) by the addition of Huh7 RNA.
Western Blotting
Protein extraction and western blotting were performed as described, 15 using rabbit polyclonal antibodies against LXRa (Abcam, Cambridge, UK), phospho-AKT (Ser 473) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), AKT (Santa Cruz Biotechnology), mouse monoclonal antibody against HCV NS5A protein (ViroStat, Portland, ME, USA) and HCV core protein (Thermo Scientific Pierce, Rockford, IL, USA). Bound primary antibody was detected with HRP (horseradish peroxidase)-conjugated anti-rabbit or anti-mouse antibodies (DAKO, Glostrup, Denmark), and blots were developed using an enhanced chemiluminescence detection system (ECL kit; Amersham Pharmacia, Uppsala, Sweden). The density of the specific bands was quantified with an imaging densitometer (Scion Image, Frederick, MD, USA).
Adenoviral Vectors
The recombinant adenovirus encoding LXRa was constructed as follows: human LXRa cDNA was kindly provided by Dr D Mangelsdorf (UT Southwestern Medical Center, Dallas, Texas). The coding sequence was released from the plasmid pCMX with KpnI-BamHI, and subcloned in the adenoviral shuttle vector pAC/CMVpLpA 29 pre-digested with the same restriction enzymes. The resulting shuttle plasmid and the pJM17 were co-transfected into 293 cells to allow homologous recombination and generate the Ad-LXRa adenovirus. Cell monolayers of human hepatoma Huh7 cell line were infected with recombinant adenovirus encoding transcription factor or with an insertless adenoviral vector (Ad-CONT) for 24 h at a multiplicity of infection (MOI) of 15-30 plaque-forming units/cell. LXRa ligand T0901317 (Sigma-Aldrich) (10 mM) was added at 24 h post infection and at 48 h post infection cells were treated with 0.1-5 mM of quercetin or IFNa-2b (0.5 and 50 U/ml). Finally, cells were harvested and analyzed.
Immunofluorescence Analysis
Immunofluorescence analysis was performed as previously described. 15 Coverslips were incubated with rabbit anti-LXRa antibody (Abcam) at 4 1C overnight. Thereafter, the secondary antibody donkey anti-rabbit conjugated with FITC (Jackson ImmunoResearch, Baltimore, PA, USA) was applied. Nuclei were stained with DAPI (blue). After washing, the coverslips were mounted on DakoCytomation Fluorescent Mounting Medium (DAKO). The preparations were analyzed with an inverted fluorescence microscope (Nikon Eclipse Ti-U).
Statistical Analysis
Results are expressed as the mean ± standard deviation. Significant differences were evaluated by one way analysis of variance (ANOVA) and Newman-Keul's test. Po0.05 was considered to be significant for a difference.
RESULTS

Quercetin is the Most Effective Inhibitor of HCV Replication
To examine the effect of treatment with different flavonoids on HCV replication efficiency, HCV-G1 cells were cultured with quercetin, kaempferol, taxifolin and apigenin in concentrations ranging from 0.1 to 5 mM or vehicle. At these very low concentrations, flavonoids exhibit no cellular toxicity and the limited antiperoxidative capacity does not interfere with their anti-HCV activity. 30 As shown in Figure 1b , all flavonoids were able to significantly reduce the HCV RNA copy number (K0.1: À 35%, K1: À 43%; T0.1: À 32%, T1: À 39%; T5: À 43%; A0.1: À 40%, A1: À 30%, vs non-treated cells), but quercetin appeared to be the most effective inhibitor of HCV replication at doses resembling human plasma concentrations upon quercetin supplementation. 31 In view of these findings, HCV-G1 cells were incubated with quercetin at concentrations of 0.1, 0.5, 1 and 5 mM alone or combined with IFNa 0.5 ( Figure 2 ). HCV-G1 cells were also treated with IFNa 50 as a control of replication inhibition ( À 90%, vs non-treated cells). As expected, quercetin significantly decreased HCV replication at all tested concentrations in a dose-dependent manner (Q0.1: À 49%, Q0.5: À 52%, Q1: À 57%, Q5: À 61%; Figure 2a (Figures 4a-c) .
Quercetin Downregulates Lipogenic Gene Overexpression Associated with HCV Replication
There is experimental evidence that LXRa induces the expression of lipogenic genes involved in fatty acid synthesis. 32 Thus, we investigated the role of the LXRa-dependent pathway in quercetin-mediated inhibition of intracytoplasmatic lipid accumulation. As shown in Figure 5 , we observed a significant induction of LXRa gene expression in repliconcontaining cells (mRNA, þ 82%, protein, þ 55%) compared with Huh7 cells. Regarding gene expression of LXRa-related lipogenic genes, as expected, we also found a significant increase in fatty acid synthase (FAS) mRNA levels in HCVreplicating cells ( þ 94%, vs Huh7) (Figure 5b ). Interestingly, quercetin was able to significantly decrease HCV-induced LXRa gene expression at all experimental concentrations (mRNA, Q0.1: À 32%, Q0.5: À 38%, Q1: À 39%, Q5: À 40%; protein, Q0.1: À 16%, Q0.5: À 19%, Q1: À 35%, Q5: À 34%) (Figures 5a and b) . Similarly, mRNA levels of FAS were significantly decreased by quercetin treatment (Q0.1: À 16%, Q0.5: À 14%, Q1: À 17%, Q5: À 20%) compared with HCV-G1 vehicle-treated cells (Figure 5b ). Noteworthy, IFNa also decreased LXRa induction (IFNa 0.5: mRNA, À 25%, protein, À 31%; IFNa 50: mRNA, À 45%, protein, À 58%; Figures 5a and b) and subsequent FAS overexpression (IFNa 0.5: À 30%; IFNa 50: À 68%) in HCV-G1 cells (Figure 5b ).
Effect of Quercetin on LXRa Overexpression Induced by Adenoviral Infection
To corroborate the effect of quercetin on LXRa gene expression, human hepatoma Huh7 cells were infected with adenoviral vector encoding LXRa transcription factor. We first examined the effect of adenoviral infection on LXRa gene expression. As exhibited in Supplementary Figure 2 , RT-qPCR, immunofluorescence microscopy and western blot assays confirmed the overexpression of the nuclear receptor LXRa in Huh7 cells infected with the adenoviral vector (protein, Huh7 Ad-0.5: þ 257%, vs Huh7 Ad-CONT). We next analyzed the effect of quercetin treatment on LXRa mRNA levels and intracytoplasmatic lipid accumulation in Huh7 Ad-0.5 cells (Figures 6a and b, respectively) . We observed that quercetin was able to dose dependently reduce LXRa overexpression caused by adenoviral infection at all tested concentrations (Q0.1: À 27%, Q0.5: À 39%, Q1: À 46%, Q5: À 58%, vs Huh7 Ad-0.5 vehicletreated cells; Figure 6a ), while the overexpression of the nuclear receptor LXRa was not affected by IFNa (Figure 6a) . Similarly, quercetin also reduced intracellular lipid accumulation at all concentrations, as depicted in representative fluorescence images of Bodipy 493/503-stained cells (Figure 6b) . Together, our results clearly indicate that quercetin exerts an inhibitory effect on LXRa expression and lipid accumulation in our in vitro model of LXRa overexpression as well as in HCV-replicating Huh7 cells. In view of these findings, we suggest that LXRa inhibition by quercetin contributes to the modulation of HCV-induced lipogenesis.
PI3K/AKT Pathway is Involved in the Inhibitory Effect of Quercetin on LXRa-Mediated Lipogenesis in HCV-G1 Cells
To investigate the role of the PI3K/AKT pathway in LXRadependent lipogenesis modulation by quercetin, we first studied the effect of quercetin on AKT activation. As shown in Figure 7a , HCV replication induced a significant increase in AKT phosphorylation ( þ 117%) compared with Huh7 cells. Furthermore, quercetin treatment significantly inhibited AKT activation at all experimental concentrations in a dosedependent manner (Q0.1: À 27%, Q0.5: À 30%, Q1: À 35%, Q5: À 43%, vs HCV-G1 vehicle-treated cells). However, IFNa 50 slightly induced AKT phosphorylation ( þ 21%) compared with HCV-G1 cells (Figure 7a ). To corroborate that quercetin inhibits HCV-mediated lipogenesis through the PI3K/AKT pathway, we next studied the effects of the PI3K-inhibitor LY294002 alone or combined with quercetin on LXRa gene expression, lipid accumulation and HCV replication efficiency. First, we confirmed that cell viability was not affected by the different treatments (Supplementary Figure 1) . As shown in Figures 7b-e, LY294002 treatment caused a significant reduction in HCV replication, LXRa mRNA levels and lipid accumulation ( À 31, À 48, and À 66%, respectively, vs HCV-G1 vehicle-treated cells). Moreover, the antiviral effect was higher when LY294002 and quercetin were Overall, these results suggest that quercetin-mediated PI3K pathway inactivation may contribute to LXRa-dependent lipogenesis modulation and inhibition of viral replication by the flavonol.
DISCUSSION
The current Food and Drug administration (FDA)-approved standard of care for chronic HCV is pegylated IFNa combined with ribavirin. However, treatment is ineffective in many HCV patients. 33 There is experimental evidence that the natural antioxidant flavonoids show therapeutic potential in the treatment of hepatitis C through inhibition of HCV replication. [21] [22] [23] The present study suggests for the first time that quercetin might exert an indirect inhibitory effect on HCV replication via oxidative/nitrosative stress blockage and subsequent modulation of PI3K-LXRa-mediated lipogenesis associated with steatosis development and hepatitis C progression.
Our preliminary results indicated that all of the flavonoids studied were able to reduce HCV replication efficiency at very low concentrations. However, quercetin appears to be the most effective modulator of HCV replication capacity in replicon-containing cells. Furthermore, it has been previously indicated that quercetin also shows antiviral activity and decreases HCV particle production in cell culture, 21 ,22 whereby we focused our study on the molecular Quercetin and HCV replication inhibition S Pisonero-Vaquero et al mechanisms involved in HCV replication regulation by this flavonol.
In the present research, a dose-dependent inhibitory effect on HCV replication was obtained with quercetin at all tested concentrations. NS5A protein expression, which is essential for HCV replication, was also reduced by quercetin treatment, as previously described. 21 Furthermore, the combination of quercetin and IFNa exerted profound inhibitory effects on NS5A protein levels and HCV replication, as shown when curcumin and IFNa were combined. 34 Similarly, our results 35, 36 In this regard, it has been described that quercetin may increase the antiviral gene expression regulated by the IFN-activated JAK-STAT pathway. 37 Nevertheless, the molecular mechanisms involved in quercetin-mediated impairment of HCV replication seem to be more complex. Thereby, quercetin may also inhibit the NS5A-driven augmentation of internal ribosomal entry site (IRES)-mediated translation 21, 38 and reduce viral production by inhibiting both NS3 and heat-shock proteins essential for HCV replication. 22 In addition to these molecular mechanisms, we investigated the contribution of oxidative/nitrosative stress and lipid metabolism modulation to the inhibition of HCV replication by quercetin.
As previously indicated, a strong relationship between oxidative/nitrosative stress and HCV infection has been reported. [4] [5] [6] [7] In the present research, quercetin was able to significantly inhibit HCV-induced ROS and RNS formation in HCV-replicating cells through its antioxidant activity. It has been also described that HCV replication induces lipid peroxidation that in turn reduces the amount of HCV RNA. 30 In our HCV replicon system, quercetin was able to decrease HCV-induced lipoperoxidation, but only slightly, thus maintaining its ability to inhibit HCV replication. IFNa treatments also reduced HCV-induced ROS/RNS generation and lipid peroxidation as previously indicated in chronic hepatitis C patients. 39, 40 The effects of IFNa on redox status seem to be directly mediated by reducing HCV replication. 41 Liver steatosis is one of the most important histopathological features in patients with chronic hepatitis C. Both viral and host factors contribute to the development of steatosis, and putative defects caused by ROS/RNS may be involved through abnormalities in lipid metabolism. 7, 9, 11 In addition, several reports suggest that lipid biosynthesis affects HCV replication. 14, 42, 43 Furthermore, some dietary flavonoids appear to regulate lipogenic genes and fatty acid synthesis in in vivo and in vitro models. [44] [45] [46] Thus, it has been previously described that quercetin decreased de novo fatty acid and triacylglycerol synthesis in rat hepatocytes. 31 In our study, quercetin was able to dose dependently decrease induced lipid accumulation in replicon-containing cells, mainly by reducing TG content, at least in part by inhibiting core expression, which interferes with TG turnover. 47 However, there is increasing evidence on the central role of non-TG lipotoxicity in the pathogenesis of steatosis. In fact, the accumulation of TG in the form of lipid droplets within the liver may be protective whereas toxic metabolites derived from FFAs could lead to steatosis. 48 In this regard, in HCV-replicating cells quercetin reduced FFA concentration, responsible for the lipotoxic effects associated with steatosis.
IFNa 50 was also able to decrease total intracytoplasmatic lipid and TG accumulation, as described in Huh7 cells expressing HCV genes. 49 Similarly, FFA concentration was reduced by IFNa, as previously observed in serum of HCVinfected patients. 50 It has been previously described that LXRa induces the expression of lipogenic genes involved in fatty acid synthesis, including its target FAS. 32 Recently, we reported that HCV replication induces LXRa-mediated intracellular lipid accumulation which in turn contributes to the efficient replication of HCV. 15 In the current study, quercetin was able to significantly decrease HCV-mediated LXRa induction and subsequent FAS overexpression at all experimental concentrations. While it has been previously described that several flavonoids reduced LXRa in non-hepatic cells, [51] [52] [53] our results indicate for the first time a role for quercetin in LXRa gene expression and lipid accumulation modulation in LXRa-overexpressing and replicon-containing Huh7 cells. Interestingly, IFNa also reversed LXRa-mediated FAS induction observed in HCV-replicating cells. A similar decrease in FAS expression by IFNa has been previously indicated in in vitro models of HCV. 49 However, in the present study IFNa was not able to repress the overexpression of the nuclear receptor LXRa in Huh7 cells infected with the adenoviral vector, suggesting that the effect of IFNa on lipogenesis modulation can be indirectly mediated by its anti-HCV activity.
We have recently shown that LY294002-mediated PI3K pathway inhibition attenuates LXRa upregulation induced by HCV expression, 15 which represents a specific mechanism through which HCV infection alters the cellular lipid profile and causes steatosis. In the current research, HCV-induced PI3K/AKT activation was dose dependently inhibited by quercetin, suggesting a role for PI3K signaling pathway activity in quercetin-mediated LXRa modulation. In this respect, LY294002, which is in fact a derivative of quercetin, 54 exerted a similar inhibitory effect on LXRa overexpression and lipid accumulation-mediated HCV replication capacity, showing an additive effect when combined with quercetin. Therefore, reduction in PI3K/AKT-LXRa-mediated hepatic fatty acid synthesis may represent an important mechanism underlying the HCV replication modulatory effect of quercetin. Similarly, PI3K/AKT-sterol regulatory element binding protein (SREBP)-1c suppression by curcumin also inhibits HCV replication in an in vitro model. 34 In our in vitro model of LXRa overexpression, quercetin could exert its inhibitory effect on LXRa expression and lipid accumulation not only through modulation of PI3K pathway but also the expression of a large number of miRNAs involved in cell signaling and metabolism, which could in turn cause downregulation of CMV-expressed LXRa. 55 However, further investigations are required to study this issue.
It has been described that quercetin bound to PI3K results in the inhibition of PI3K activity. 56 Otherwise, it has been suggested that HCV gene expression induces activation of PI3K/AKT via oxidative stress and calcium signaling. 26 As previously indicated, HCV proteins induce oxidative stressmediated Ca 2 þ homeostasis alterations, 6 which might underlie the effects of HCV expression on the PI3K/AKT pathway. In fact, it has been shown that quercetin suppressed the endoplasmic reticulum stress caused by Ca 2 þ dynamics dysregulation by the inhibition of PI3K. 57 Thereby, quercetin can also modulate the PI3K/AKT pathway by reducing HCVrelated ROS and RNS generation.
The PI3K pathways have emerged as a critical additional component of IFN-induced signaling. 58 Thus, the IFNinduced PI3K/AKT pathway is the essential signal for cell survival and thought to be one mechanism for chronic HCV infection. 58, 59 In this study, IFNa treatment is able to interfere with the PI3K/AKT pathway as shown by a dosedependent induction of Ser 473 phosphorylation of AKT. However, the treatment with PI3K inhibitors did not influence IFN-induced anti-HCV replication, indicating that its anti-HCV activity is not PI3K/AKT dependent, as previously reported. 60 In conclusion, our results suggest that quercetin might exert its inhibitory effect on HCV replication at least in part through oxidative/nitrosative stress inhibition and subsequent lipid metabolism modulation, by reducing PI3K/ AKT-mediated LXRa overexpression and lipid accumulation associated with steatosis development and hepatitis C progression. Thus, the importance of therapeutic approaches focusing on oxidative/nitrosative stress and associated steatosis in HCV patients is expected to increase in the near future.
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